SOPHiA GENETICS S.A.
- Open
- 5.66
- Day high
- 5.90
- Day low
- 5.48
- Prev close
- 5.77
- Volume
- 218K
- Mkt cap
- $411M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 9.0
- P/S
- 5.1
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.5M over the last 3 months (1 open-market buy, 78 sales)
- 🏛Institutions accumulating (13F)
SOPHiA GENETICS S.A. (SOPH) is a Healthcare company listed on NASDAQ. The stock is up 75% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 78 sales (SEC Form 4).
SOPHiA GENETICS S.A. (SOPH) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SOPH earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.23 | $-0.27 | -16.1% | $22M | +6.3% |
| Mar 3, 2026 | $-0.24 | $-0.28 | -16.7% | $22M | +5.9% |
| Nov 4, 2025 | $-0.20 | $-0.30 | -50.0% | $19M | -5.0% |
| Mar 4, 2025 | $-0.23 | $-0.23 | +0.0% | $18M | +4.4% |
| Mar 5, 2024 | $-0.25 | $-0.37 | -48.0% | $17M | -1.6% |
| Mar 7, 2023 | $-0.34 | $-0.22 | +35.3% | $13M | -3.6% |
| Mar 15, 2022 | $-0.34 | $-0.33 | +2.9% | $11M | -2.3% |
| Nov 10, 2021 | $-0.38 | $-0.35 | +7.9% | $10M | — |
| Sep 9, 2021 | $-0.39 | $-0.31 | +20.5% | $10M | — |
| Dec 31, 2020 | — | $-0.22 | — | $8M | — |
| Sep 30, 2020 | — | $-0.22 | — | $7M | — |
| Jun 30, 2020 | — | $-0.16 | — | $6M | — |
SOPH insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Camblong Jurgidirector, officer: Chief Executive Officer | Sell | 31,940 | $5.84 |
| Jun 29, 2026 | Camblong Jurgidirector, officer: Chief Executive Officer | Sell | 1,373 | $5.70 |
| Jun 29, 2026 | Camblong Jurgidirector, officer: Chief Executive Officer | Sell | 18,129 | $5.73 |
| Jun 29, 2026 | Camblong Jurgidirector, officer: Chief Executive Officer | Option | 31,940 | $3.16 |
| Jun 26, 2026 | Menu Philippeofficer: Chief Medical Officer | Sell | 5,000 | $5.50 |
| Jun 26, 2026 | Verma Abhimanyuofficer: Chief Technology Officer | Sell | 6,944 | $5.51 |
| Jun 23, 2026 | Muken Rossofficer: President | Sell | 422 | $5.38 |
| Jun 23, 2026 | CARDOZA GEORGEofficer: Chief Financial Officer | Sell | 774 | $5.38 |
| Jun 22, 2026 | HIBBS KATHY Ldirector | Grant | 19,724 | $5.46 |
| Jun 22, 2026 | Cox Troydirector | Grant | 28,818 | $5.46 |
| Jun 22, 2026 | Cox Troydirector | Grant | 19,724 | $5.46 |
| Jun 22, 2026 | HIRSCH DIDIERdirector | Grant | 28,818 | $5.46 |
| Jun 22, 2026 | HIRSCH DIDIERdirector | Grant | 19,724 | $5.46 |
| Jun 22, 2026 | Cossery Jean-Micheldirector | Grant | 28,818 | $5.46 |
| Jun 22, 2026 | Cossery Jean-Micheldirector | Grant | 19,724 | $5.46 |
Source: SOPH SEC Form 4 filings, latest Jun 29, 2026. For informational purposes only — not investment advice.
See the full SOPH insider & 13F page →SOPHiA GENETICS S.A. company profile
Overview
SOPHiA GENETICS SA (NASDAQ:SOPH) is a Swiss healthcare technology company founded in 2011 and headquartered in Saint-Sulpice, Switzerland. The company went public in July 2021, positioning itself as a leader in data-driven medicine through artificial intelligence and cloud computing. SOPHiA GENETICS has built a global platform that serves hospitals, laboratories, and biopharmaceutical companies across more than 70 countries, with nearly 800 healthcare institutions using its technology to analyze genomic data for precision medicine applications.
Business
SOPHiA GENETICS operates in the healthcare informatics sector, specifically focusing on genomic data analysis and precision medicine. The company's core offering is the SOPHiA DDM (Data-Driven Medicine) platform, a cloud-based software-as-a-service solution that analyzes complex genomic data to help healthcare providers make more informed treatment decisions. To understand what SOPHiA GENETICS does, it's important to know that modern medicine increasingly relies on analyzing a patient's genetic makeup to determine the best treatment approach, particularly in cancer care. When a patient has a tumor biopsy or blood sample taken, that sample contains DNA that can reveal specific genetic mutations driving the disease. However, analyzing this genetic data requires sophisticated computational tools and expertise that most hospitals and laboratories lack. The SOPHiA DDM platform solves this problem by providing automated analysis of genomic sequencing data. Healthcare providers send their raw genetic data to SOPHiA's cloud platform, which uses artificial intelligence and machine learning algorithms to identify clinically relevant genetic variations, predict treatment responses, and generate actionable insights for physicians. The platform covers multiple medical applications including oncology (cancer treatment), rare diseases, and inherited disorders. The company operates through two main business segments: 1. Clinical genomics services (approximately 85-90% of revenue): This involves processing genomic analyses for hospitals and diagnostic laboratories worldwide. Customers pay per analysis, typically ranging from hundreds to thousands of dollars depending on the complexity of the test. 2. Biopharmaceutical partnerships (approximately 10-15% of revenue): SOPHiA collaborates with pharmaceutical companies to analyze patient data for drug development, clinical trials, and companion diagnostics that help determine which patients will respond best to specific treatments.
Revenue model
SOPHiA GENETICS generates revenue primarily through a usage-based pricing model where customers pay per genomic analysis performed on the platform. Healthcare institutions such as hospitals and diagnostic laboratories are the primary paying customers, with pricing typically ranging from several hundred to several thousand dollars per analysis depending on the complexity and type of genomic test. The company's business model benefits from several favorable dynamics. As genomic testing becomes more mainstream in healthcare, particularly in oncology where personalized treatment is increasingly standard of care, demand for SOPHiA's analytical capabilities grows. The platform exhibits network effects - as more institutions use the system and contribute data, the artificial intelligence algorithms become more accurate and valuable to all users. Additionally, customers tend to increase their usage over time as they expand genomic testing across more patient populations and disease areas. Several factors can positively impact SOPHiA's margins and growth. Declining costs of DNA sequencing technology make genomic testing more accessible, driving higher volumes through the platform. Regulatory trends favoring personalized medicine, such as FDA approvals for companion diagnostics, expand the addressable market. The company's partnership with Memorial Sloan Kettering Cancer Center to offer MSK-ACCESS and MSK-IMPACT applications provides access to premium, higher-priced genomic tests. Conversely, margin pressure can arise from competitive pricing in the genomics market, particularly from larger players like Illumina or emerging direct competitors. Healthcare budget constraints, especially in the biopharmaceutical sector, can slow customer adoption and reduce spending per analysis. Additionally, regulatory changes affecting laboratory-developed tests or data privacy requirements could increase compliance costs or limit market access in certain regions.
Competitive moat
SOPHiA GENETICS possesses a moderate but growing competitive moat built primarily around data network effects and specialized expertise. The company's strongest defensive position comes from its accumulated dataset of over 2 million genomic patient profiles analyzed across diverse populations and geographies. This data advantage enables the platform's AI algorithms to provide more accurate and comprehensive analysis compared to competitors with smaller datasets, creating a virtuous cycle where better performance attracts more customers and more data. The company also benefits from switching costs and integration complexity. Once healthcare institutions integrate SOPHiA's platform into their laboratory workflows and train staff on the system, changing to alternative solutions requires significant time, cost, and operational disruption. The platform's global regulatory compliance across multiple jurisdictions and its ability to handle diverse genomic applications create additional barriers for competitors to replicate. However, SOPHiA's moat faces meaningful competitive threats. Large technology companies like Microsoft (with whom SOPHiA partners) and Google have substantial resources to develop competing genomic analysis platforms. Established healthcare IT companies such as Veracyte, Foundation Medicine (owned by Roche), or Guardant Health possess deeper financial resources and stronger customer relationships. Additionally, major sequencing equipment manufacturers like Illumina could potentially integrate similar analytical capabilities directly into their instruments, potentially bypassing SOPHiA's platform entirely. The competitive landscape is intensifying as genomic analysis becomes more commoditized and as artificial intelligence tools become more accessible. SOPHiA's long-term moat strength will depend on its ability to maintain technological leadership, expand its data advantage, and develop deeper partnerships with key healthcare institutions and pharmaceutical companies.
Risks & safety
SOPHiA GENETICS presents a moderate margin of safety from a solvency perspective but faces ongoing profitability challenges that create execution risk. **Cash and Liquidity Position:** - Strong cash position of $68.5 million plus $35 million undrawn credit facility - Current ratio of 3.1x indicates solid short-term liquidity - Current cash burn rate of approximately $40-50 million annually provides roughly 2-3 years of runway **Debt and Solvency:** - Low debt-to-equity ratio of 0.35x indicates minimal leverage risk - Total liabilities of $61 million against $147 million in assets - No significant debt maturities creating near-term refinancing pressure **Valuation Metrics:** - Trading at 2.6x price-to-book ratio with negative earnings - Enterprise value reflects significant discount to historical growth companies in healthcare IT - Revenue multiple appears reasonable given 10-17% expected growth rates **Other Considerations:** - Company targeting EBITDA breakeven by end of 2026, requiring sustained execution - Dependence on customer implementation timelines creates revenue timing risk - Limited operating leverage achieved to date despite revenue growth
Recent development
Over the past few years, SOPHiA GENETICS has undergone significant strategic evolution focused on accelerating growth and improving operational efficiency. The company has dramatically improved its customer implementation capabilities, implementing 33 new customers in Q1 2025 compared to an average of 23 per quarter in 2024. This improvement stems from enhanced tooling, automation, process industrialization, and selective headcount additions in field application support. A major strategic pivot has been the expansion into premium genomic applications through partnerships with Memorial Sloan Kettering Cancer Center. The company launched MSK-ACCESS liquid biopsy and MSK-IMPACT comprehensive genomic profiling applications, which command significantly higher pricing (potentially $100,000+ per customer) compared to standard genomic tests. These applications have gained traction with 18 customers adopting MSK-ACCESS across multiple continents. The company has also restructured its biopharmaceutical business to focus on smaller, more targeted opportunities rather than pursuing large-scale partnerships that proved difficult to execute. This strategic shift emphasizes post-approval market access activities and companion diagnostics development, moving away from early-stage drug development collaborations that had longer sales cycles and uncertain outcomes. Geographically, SOPHiA has achieved remarkable success in North American market expansion, with the region showing 30-40% volume growth consistently over recent quarters. The company has also strengthened its presence in high-growth markets including Asia Pacific, the United Kingdom, and Germany while reallocating resources away from slower-growing European markets. Recent leadership changes include promoting Ross Muken to Company President and bringing in George Cardoza as Chief Financial Officer, signaling a focus on operational excellence and financial discipline as the company approaches its targeted path to profitability by end of 2026.
SOPH company profile · for informational purposes only — not investment advice.
Track SOPH with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free